Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Biological Staging of the Parkinson’s Progression Markers Initiative (PPMI) Cohort Using the Research Neuronal a-synuclein Disease Integrated Staging System (NSD-ISS)
Movement Disorders
P11 - Poster Session 11 (5:30 PM-6:30 PM)
3-009
NSD is defined by pathologic neuronal alpha-synuclein (S) and eventual dopaminergic neuronal dysfunction (D), independent of clinical features or specific syndrome. NSD-ISS integrates the biological anchors (S,D) and degree of functional impairment caused by motor, cognitive or other non-motor signs (Simuni et al, In Press).
To apply  Neuronal α-Synuclein Disease Integrated Staging System (NSD-ISS) in PPMI participants
Apply NSD-ISS staging criteria  to PPMI participants at baseline

On 6/12/23, 802 of 2307 were S+ and reported here. 695 S- are not included. For 810 S status pending, results will be added.

Among 507 sPD: 2% were NSD-ISS Stage 2A (S+,D-, subtle signs/symptoms, no functional impairment), 24% NSD-ISS Stage 2B (S+,D+, subtle signs/symptoms, no functional impairment), 64% NSD-ISS Stage 3 (S+,D+, signs/symptoms +, slight functional impairment), 10% NDS-ISS Stage 4 or 5 (S+,D+, signs/symptoms +, mild or moderate functional impairment).

Among 87 LRRK2 PD: 11% NSD-ISS Stage 2B, 61% Stage 3, 27% Stage > 4

Among 56 GBA PD: 13% NSD-ISS Stage 2B, 61% Stage 3, 26% Stage > 4

Among 9 SNCA PD: 11% NSD-ISS Stage 2B, 33% Stage 3, 55% Stage > 4

Among 63 REM Sleep Behavior Disorder: 41% NSD-ISS Stage 2A, 41% Stage 2B, 11% Stage 3, 7% Stage >4.

Among 38 hyposmics: 45% Stage 2A, 47% Stage 2B, 8% Stage 3. Among 56 GBA PD: 13% Stage 2B, 61% Stage 3, 27% Stage > 4.

Among 11 GBA NMC: 36% NSD-ISS Stage 1A (S+/D-, no signs/symptoms), 55% Stage 2A, 9% Stage 3. Among 87 LRRK2 PD: 11% Stage 2B, 61% Stage 3, 26% Stage > 4.

Among 12 LRRK2 NMC: 33% Stage 1A, 17% NSD_ISS Stage 1B (S+,D+, no signs/symptoms), 33% Stage 2A, 17% Stage 2B.


We present the first data-driven application of the NSD-ISS, highlighting the heterogeneity of the biological stages in a phenotypically homogeneous cohort
Authors/Disclosures
Caroline M. Tanner, MD, PhD, FAAN (University of California San Francisco, Weill Institute for Neurosciences)
PRESENTER
Dr. Tanner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Evidera. Dr. Tanner has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Neurocrine. Dr. Tanner has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Jazz Pharmaceuticals/Cavion. Dr. Tanner has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bial . Dr. Tanner has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Supernus. Dr. Tanner has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche Genentech. The institution of Dr. Tanner has received research support from Gateway LLC. The institution of Dr. Tanner has received research support from Roche\Genentech. The institution of Dr. Tanner has received research support from Michael J Fox Foundation . The institution of Dr. Tanner has received research support from National Institute of Health . The institution of Dr. Tanner has received research support from Department of Defense. Dr. Tanner has received personal compensation in the range of $500-$4,999 for serving as a Faculty, CME presentation with Medscape /WebND.
Tanya Simuni, MD, FAAN (Northwestern University Feinberg School of Medicien) Dr. Simuni has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for cadia, AcureX, Adamas, AskBio, Amneal, Blue Rock Therapeutics, Caraway Therapeutics, Critical Path for Parkinson's Consortium (CPP), Denali, Michael J Fox Foundation, Neuroderm, Sanofi, Sinopia, Roche, Takeda and Vanqua Bio. Dr. Simuni has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for of Koneksa, Neuroderm, Sanofi, UCB, AcureX, Adamas, AskBio, Biohaven, Denali, GAIN, Neuron23 and Roche. Dr. Simuni has received research support from Amneal, Biogen, Neuroderm, Prevail, Roche, and UCB and an investigator for NINDS, MJFF, Parkinson's Foundation.
Lana Chahine, MD, FAAN (University of Pittsburgh) Dr. Chahine has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Gray Matters Technology. The institution of Dr. Chahine has received research support from UPMC. The institution of Dr. Chahine has received research support from MJFF. The institution of Dr. Chahine has received research support from Denali/Biogen. Dr. Chahine has received publishing royalties from a publication relating to health care.
Kathleen Poston, MD, FAAN (Stanford University) Dr. Poston has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Curasen Therapeutics, INC. Dr. Poston has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Amprion, INC. Dr. Poston has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for NIH. Dr. Poston has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Movement Disorders Journal. Dr. Poston has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Annals of Neurology. Dr. Poston has stock in Curasen Therapeutics, INC. Dr. Poston has stock in Amprion, INC. The institution of Dr. Poston has received research support from NIH. The institution of Dr. Poston has received research support from Michael J Fox Foundation. The institution of Dr. Poston has received research support from Alzheimer's Drug Discovery Foundation . The institution of Dr. Poston has received research support from Lewy Body Dementia Association. Dr. Poston has received intellectual property interests from a discovery or technology relating to health care.
Michael Brumm No disclosure on file
Sohini Chowdhury No disclosure on file
Christopher Coffey, PhD, FAAN (University of Iowa) Dr. Coffey has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Heart Association. The institution of Dr. Coffey has received research support from NIH. The institution of Dr. Coffey has received research support from Michael J Fox Foundation.
Luis Concha (Amprion) No disclosure on file
Tien Dam No disclosure on file
Peter Di Biaso (WCG Clinical) No disclosure on file
Tatiana Foroud, PhD (Indiana University School of Medicine) The institution of Dr. Foroud has received research support from NIH. The institution of Dr. Foroud has received research support from Michael J. Fox Foundation. The institution of Dr. Foroud has received research support from Parkinson Foundation. Dr. Foroud has received personal compensation in the range of $500-$4,999 for serving as a Member of an Advisory Committee with Mayo Clinic, University of Pennsylvania, Allen Institute, Mt. Sinai, Van Andel Institute.
Mark Frasier No disclosure on file
Caroline Gochanour (University of Iowa CTSDMC) No disclosure on file
Danna L. Jennings, MD (Denali Therapeutics) Dr. Jennings has received personal compensation for serving as an employee of Denali Therapeutics . Dr. Jennings has received stock or an ownership interest from Denali Therapeutics.
Karl D. Kieburtz, MD (University of Rochester Medical Center) Dr. Kieburtz has received personal compensation for serving as an employee of Clintrex Research Corporation. Dr. Kieburtz has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Kieburtz has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lilly. Dr. Kieburtz has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Janssen. Dr. Kieburtz has stock in Clintrex Research Corp. Dr. Kieburtz has stock in Hoover Brown. An immediate family member of Dr. Kieburtz has stock in Hoover Brown. Dr. Kieburtz has stock in Safe Therapeutics. The institution of Dr. Kieburtz has received research support from NIH. The institution of Dr. Kieburtz has received research support from Michae J Fox Foundation.
Catherine Kopil No disclosure on file
Kalpana Merchant No disclosure on file
Brit Mollenhauer No disclosure on file
Thomas J. Montine, MD, PhD Dr. Montine has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Enable Medicine. Dr. Montine has stock in Enable Medicine. The institution of Dr. Montine has received research support from NIH. The institution of Dr. Montine has received research support from MJFF. Dr. Montine has received intellectual property interests from a discovery or technology relating to health care. Dr. Montine has received publishing royalties from a publication relating to health care.
Kelly Nudelman No disclosure on file
Gennaro Pagano, MD, PhD, eMBA (F. Hoffmann-La Roche Ltd) Prof. Pagano has received personal compensation for serving as an employee of F.Hoffmann-La Roche Ltd. Prof. Pagano has stock in F.Hoffmann La Roche Ltd.
John P. Seibyl, MD Dr. Seibyl has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Invicro. Dr. Seibyl has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen. Dr. Seibyl has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Life Molecular Imaging. Dr. Seibyl has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche. Dr. Seibyl has received stock or an ownership interest from Invicro.
Todd Sherer (Michael J Fox Foundation) No disclosure on file
Andrew Singleton An immediate family member of Andrew Singleton has received personal compensation for serving as an employee of GeneDx. Andrew Singleton has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Nature Partner Journals Parkinson Disease. Andrew Singleton has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Movement Disorders Journal. An immediate family member of Andrew Singleton has stock in GeneDx. The institution of Andrew Singleton has received research support from Michael J Fox Foundation. Andrew Singleton has received intellectual property interests from a discovery or technology relating to health care. Andrew Singleton has received intellectual property interests from a discovery or technology relating to health care.
Diane Stephenson (Critical Path Institute) Diane Stephenson has received personal compensation for serving as an employee of Critical Path Institute.
Matthew B. Stern, MD Dr. Stern has received personal compensation for serving as an employee of Mediflix, Inc. Dr. Stern has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for biogen. Dr. Stern has received personal compensation in the range of $100,000-$499,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Neuroderm.
Claudio Soto (University of Texas Medical Branch) No disclosure on file
Eduardo S. Tolosa, MD Dr. Tolosa has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Prevail. Dr. Tolosa has received personal compensation in the range of $500-$4,999 for serving as a Consultant for MSD . Dr. Tolosa has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Tolosa has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Teva. Dr. Tolosa has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for AbbVie . Dr. Tolosa has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Boehringer Ingelheim. Dr. Tolosa has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Ever Neuropharm. Dr. Tolosa has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Esteve. The institution of Dr. Tolosa has received research support from Instituto de Salud CArlos III. Dr. Tolosa has received research support from MJFF. Dr. Tolosa has received publishing royalties from a publication relating to health care.
Daniel Weintraub Daniel Weintraub has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Clintrex. Daniel Weintraub has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. Daniel Weintraub has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen. Daniel Weintraub has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sage. Daniel Weintraub has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Scion. Daniel Weintraub has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Signant. Daniel Weintraub has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sunovion. Daniel Weintraub has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Modality.ai. Daniel Weintraub has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cerevel. Daniel Weintraub has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CuraSen. Daniel Weintraub has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Takeda. Daniel Weintraub has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Boehringer Ingelheim. Daniel Weintraub has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Daniel Weintraub has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Acadia. Daniel Weintraub has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Movement Disorder Society. The institution of Daniel Weintraub has received research support from NIH. The institution of Daniel Weintraub has received research support from Fox Foundation. The institution of Daniel Weintraub has received research support from IPMDS. Daniel Weintraub has received intellectual property interests from a discovery or technology relating to health care.
Yuge Xiao No disclosure on file
Andrew D. Siderowf, MD Dr. Siderowf has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Siderowf has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Mitsubishi. Dr. Siderowf has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Boehringer-Ingelheim. Dr. Siderowf has received personal compensation in the range of $500-$4,999 for serving as a Consultant for askbio. Dr. Siderowf has received personal compensation in the range of $500-$4,999 for serving as a Consultant for capsida. Dr. Siderowf has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Prilenia. Dr. Siderowf has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Wave. Dr. Siderowf has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Neurogastrix. Dr. Siderowf has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Prevail. Dr. Siderowf has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alerity. Dr. Siderowf has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Clintrex. Dr. Siderowf has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Inhibikase.
Werner Poewe, MD (University Hospital of Neurology) Werner Poewe, MD has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Affiris . Werner Poewe, MD has received personal compensation in the range of $50,000-$99,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alterity, AbbVie, BIAL, Biogen, Britannia, Lilly, Lundbeck, Neuroderm, Neurocrine, Denali Pharmaceuticals, ,Roche, Takeda, UCB and Zambon . Werner Poewe, MD has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for AbbVie, Britannia, BIAL, STADA, Lundbeck, Zambon. The institution of Werner Poewe, MD has received research support from MJFF; EU Horizon programme. Werner Poewe, MD has a non-compensated relationship as a Committee member with Movement Disorder Society that is relevant to AAN interests or activities.
Kenneth L. Marek, MD (IND) Dr. Marek has received personal compensation for serving as an employee of IND. Dr. Marek has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for invicro. Dr. Marek has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche. Dr. Marek has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi. Dr. Marek has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biohaven. Dr. Marek has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for takeda. Dr. Marek has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Denali. Dr. Marek has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Koneksa. Dr. Marek has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Xingimaging. Dr. Marek has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neuron23. Dr. Marek has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lilly. Dr. Marek has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biohaven. Dr. Marek has received research support from Michael J Fox Foundation.